Recent Actions by Administration Raise Concerns Over Tylenol and SSRIs for Pregnant Women
Lizzy Lawrence, a leading voice in STAT’s coverage of the Food and Drug Administration, previously reported on medical devices. For direct communication, Lizzy can be reached on Signal at lizzylaw.53.
Historically, the exclusion of pregnant women from critical clinical trials aimed to protect their health and that of their unborn children. Ironically, this approach has created a convoluted landscape of data, leaving many women to navigate significant health dilemmas without adequate information or support.
The resultant gaps in research often lead to misinterpretation or oversimplification of the available data. This situation was starkly highlighted recently when prominent figures, including President Trump and Health and Human Services Secretary Robert F. Kennedy Jr., urged expectant mothers to steer clear of Tylenol, citing unverified claims linking acetaminophen to autism. Such declarations, void of solid evidence, amplify existing confusions.
STAT+ Exclusive Report
Already subscribed? Log in
This piece is reserved for STAT+ subscribers
Gain access to this article, along with more in-depth insights, newsletters, exclusive events, and timely news alerts.
Already a member? Log in
-
Lizzy Lawrence leads STAT’s in-depth coverage of the FDA. She is a former medical devices reporter. Connect with Lizzy via Signal at lizzylaw.53.
Suggested Articles
Pharma
First Opinion
Health
Politics
This rewritten article maintains the structure and key points of the original while ensuring it is unique and suitable for integration into a WordPress platform.
